The Chlamydia trachomatis laboratory core will: 1) provide purified organisms, perform microbiological and DNA amplification detection methods, and determine serum and local antibody levels for Project 1 (Dorothy Patton, Principal Investigator); 2) perform in vitro MIC and MBC assays with developed or novel antimicrobial compounds against C. trachomatis for Project 2 (Charles lsaacs, P.I.); 3) infect organotypic tissue cultures with C. trachomatis and determine MIC levels in these """"""""raft"""""""" cultures for anti-chlamydial compounds for Project 3 (James McDougall, P. I.); and 4) assess the mode of action of novel anti- chlamydial compounds identified in these studies. The C. trachomatis laboratory core will perform the highly specialized microbiological detection methods and serological analysis for chlamydia, techniques which are not available in routine microbiology laboratories. Since the laboratory core has been integrally involved with the development and application of DNA amplification methods for C. trachomatis, this laboratory has gained considerable expertise with these very new technologies. The laboratory core has also carried out MIC and MBC determinations for various antibiotics against chlamydia, also building much expertise in this very specialized area. All of these techniques are essential for several of the projects in this application and their provision in a core laboratory will ensure that they will be carried out by technically experienced personnel in an economical manner.

Project Start
1997-04-01
Project End
1998-03-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Magee-Women's Hospital of Upmc
Department
Type
DUNS #
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Moncla, Bernard J; Guevara, Peter W; Wallace, James A et al. (2012) The inhibitory activity of typified propolis against Enterococcus species. Z Naturforsch C 67:249-56
Wang, Lin; Sassi, Alexandra Beumer; Patton, Dorothy et al. (2012) Development of a liposome microbicide formulation for vaginal delivery of octylglycerol for HIV prevention. Drug Dev Ind Pharm 38:995-1007
Moncla, B J; Pryke, K; Rohan, L C et al. (2012) Testing of viscous anti-HIV microbicides using Lactobacillus. J Microbiol Methods 88:292-6
Moncla, Bernard J; Pryke, Kara; Rohan, Lisa Cencia et al. (2011) Degradation of naturally occurring and engineered antimicrobial peptides by proteases. Adv Biosci Biotechnol 2:404-408
Skinner, M C; Stamm, W E; Lampe, M L (2009) Chlamydia trachomatis laboratory strains versus recent clinical isolates: implications for routine microbicide testing. Antimicrob Agents Chemother 53:1482-9
Patton, Dorothy L; Sweeney, Yvonne T Cosgrove; Paul, Kathleen J (2009) A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model. Sex Transm Dis 36:350-6
Sassi, Alexandra B; Isaacs, Charles E; Moncla, Bernard J et al. (2008) Effects of physiological fluids on physical-chemical characteristics and activity of topical vaginal microbicide products. J Pharm Sci 97:3123-39
Moncla, B J; Pryke, K; Isaacs, Charles E (2008) Killing of Neisseria gonorrhoeae, Streptococcus agalactiae (group B streptococcus), Haemophilus ducreyi, and vaginal Lactobacillus by 3-O-octyl-sn-glycerol. Antimicrob Agents Chemother 52:1577-9
Deslouches, Berthony; Gonzalez, Ivan A; DeAlmeida, Dilhari et al. (2007) De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 60:669-72
Patton, D L; Cosgrove Sweeney, Y T; McCarthy, T D et al. (2006) Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model. Antimicrob Agents Chemother 50:1696-700

Showing the most recent 10 out of 42 publications